P2.12-07 Phase II Trial of LP-300 + Pemetrexed/Carboplatin in Patients Who Never Smoked with Lung Adenocarcinoma After TKI Progression

LP-300 targets molecular pathways that are commonly found among patients with lung adenocarcinoma who have never smoked. This agent is a multi-targeting modulator of enzymatic activity of EGFR, ALK, MET, and ROS1 capable of inactivating tumor-driving oncogenes via covalent modification of membrane receptors. LP-300 also acts as a chemo-sensitizer by inactivating thioredoxin, glutaredoxin, and peroxiredoxin, which are proteins that modulate cellular redox status and in turn drug resistance. The prior phase III trial evaluating LP-300 with paclitaxel/cisplatin demonstrated a marginal increase in survival in the overall study population.